The COVID-19 pandemic and the use of MS disease-modifying therapies.
作者信息
Giovannoni Gavin, Hawkes Chris, Lechner-Scott Jeannette, Levy Michael, Waubant Emmanuelle, Gold Julian
机构信息
Blizard Institute, Barts and The London School of Medicine and Dentistry, 4 Newark Street, London, E1 2AT, UK.
Blizard Institute, Barts and The London School of Medicine and Dentistry, 4 Newark Street, London, E1 2AT, UK.
出版信息
Mult Scler Relat Disord. 2020 Apr;39:102073. doi: 10.1016/j.msard.2020.102073. Epub 2020 Mar 27.
Abstract
摘要
相似文献
1
The COVID-19 pandemic and the use of MS disease-modifying therapies.新冠疫情与多发性硬化症疾病修正疗法的使用
Mult Scler Relat Disord. 2020 Apr;39:102073. doi: 10.1016/j.msard.2020.102073. Epub 2020 Mar 27.
2
Multiple Sclerosis Disease-Modifying Therapies in the COVID-19 Era.新冠疫情时代的多发性硬化症疾病修正疗法
Ann Neurol. 2020 Dec;88(6):1062-1064. doi: 10.1002/ana.25907. Epub 2020 Sep 30.
3
Are patients with multiple sclerosis (MS) at higher risk of COVID-19 infection?患有多发性硬化症（MS）的患者感染新冠病毒（COVID-19）的风险更高吗？
Neurol Sci. 2020 Sep;41(9):2315-2316. doi: 10.1007/s10072-020-04570-8. Epub 2020 Jul 7.
4
Is Gradual and Controlled Approach to Herd Protection a Valid Strategy to Curb the COVID-19 Pandemic?逐步且可控的群体保护方法是遏制新冠疫情的有效策略吗？
Indian Pediatr. 2020 Jun 15;57(6):505-507. doi: 10.1007/s13312-020-1844-4. Epub 2020 May 6.
5
COVID-19 will change MS care forever - No.新冠疫情将永远改变多发性硬化症的护理——不。
Mult Scler. 2020 Sep;26(10):1149-1151. doi: 10.1177/1352458520929971. Epub 2020 Jun 22.
6
Rehabilitation Recommendations for Multiple Sclerosis Patients during the COVID-19 Pandemic.新冠疫情期间多发性硬化症患者的康复建议
Arch Iran Med. 2020 Jul 1;23(7):509-510. doi: 10.34172/aim.2020.51.
7
Developing Covid-19 Vaccines at Pandemic Speed.以大流行速度研发新冠疫苗。
N Engl J Med. 2020 May 21;382(21):1969-1973. doi: 10.1056/NEJMp2005630. Epub 2020 Mar 30.
8
The paramount importance of serological surveys of SARS-CoV-2 infection and immunity.新型冠状病毒2（SARS-CoV-2）感染与免疫血清学调查的至关重要性。
Eur J Epidemiol. 2020 Apr;35(4):331-333. doi: 10.1007/s10654-020-00635-2. Epub 2020 Apr 21.
9
[Not Available].[无可用内容]
Rev Med Suisse. 2020 Jun 3;16(696):1174-1175.
10
COVID-19-a very visible pandemic.新冠疫情——一场极具影响力的大流行病。
Lancet. 2020 Aug 8;396(10248):e17. doi: 10.1016/S0140-6736(20)31675-5.
引用本文的文献
1
Impact of High-Efficacy Therapies for Multiple Sclerosis on B Cells.高效多发性硬化症疗法对B细胞的影响。
Cells. 2025 Apr 17;14(8):606. doi: 10.3390/cells14080606.
2
MS treatment trends before, during, and after the COVID-19 pandemic: insights from the German MS Register.新冠疫情之前、期间及之后的多发性硬化症治疗趋势：来自德国多发性硬化症登记处的见解
J Neurol. 2025 Mar 26;272(4):294. doi: 10.1007/s00415-025-13010-6.
3
COVID-19 and multiple sclerosis: challenges and lessons for patient care.2019冠状病毒病与多发性硬化症：患者护理面临的挑战与经验教训
Lancet Reg Health Eur. 2024 Aug 22;44:100979. doi: 10.1016/j.lanepe.2024.100979. eCollection 2024 Sep.
4
Do immunosuppressive treatments influence immune responses against adenovirus-based COVID-19 vaccines in patients with multiple sclerosis? An Argentine multicenter study.免疫抑制治疗是否会影响多发性硬化症患者对基于腺病毒的 COVID-19 疫苗的免疫反应？一项阿根廷多中心研究。
Front Immunol. 2024 Aug 19;15:1431403. doi: 10.3389/fimmu.2024.1431403. eCollection 2024.
5
A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic.一项多中心纵向研究分析了 COVID-19 大流行期间多发性硬化症的疾病修正治疗处方模式。
J Neurol. 2024 Sep;271(9):5813-5824. doi: 10.1007/s00415-024-12518-7. Epub 2024 Jun 27.
6
Assessment of COVID-19 vaccine attitude in people with multiple sclerosis, its correlation with demographic factors, and fear of coronavirus: A cross-sectional survey.多发性硬化症患者对新冠疫苗的态度评估、其与人口统计学因素的相关性以及对冠状病毒的恐惧：一项横断面调查。
Curr J Neurol. 2022 Oct 7;21(4):230-235. doi: 10.18502/cjn.v21i4.11720.
7
Era of COVID-19 in Multiple Sclerosis Care.COVID-19 时代下的多发性硬化症护理。
Neurol Clin. 2024 Feb;42(1):319-340. doi: 10.1016/j.ncl.2023.06.006. Epub 2023 Jun 23.
8
Outcome of COVID-19 Infection in Patients With Multiple Sclerosis Who Received Disease-Modifying Therapies: A Systematic Review and Meta-Analysis.接受疾病修正治疗的多发性硬化症患者感染新冠病毒的结果：一项系统评价和荟萃分析
J Clin Neurol. 2023 Jul;19(4):381-391. doi: 10.3988/jcn.2022.0348. Epub 2023 Mar 13.
9
Multiple sclerosis patients' response to COVID-19 pandemic and vaccination in Egypt.埃及多发性硬化症患者对新冠疫情及疫苗接种的反应
Egypt J Neurol Psychiatr Neurosurg. 2022;58(1):131. doi: 10.1186/s41983-022-00573-8. Epub 2022 Nov 17.
10
Immune responses following COVID-19 infection in multiple sclerosis patients using immunomodulatory therapy.COVID-19 感染后使用免疫调节疗法的多发性硬化症患者的免疫反应。
Acta Neurol Belg. 2023 Oct;123(5):1885-1892. doi: 10.1007/s13760-022-02125-6. Epub 2022 Nov 4.
本文引用的文献
1
The proximal origin of SARS-CoV-2.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的近端起源。
Nat Med. 2020 Apr;26(4):450-452. doi: 10.1038/s41591-020-0820-9.
2
Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases.COVID-19 大流行期间和其他新发传染病疫情中严重急性呼吸窘迫综合征的体外膜肺氧合服务规划和供应。
Lancet Respir Med. 2020 May;8(5):518-526. doi: 10.1016/S2213-2600(20)30121-1. Epub 2020 Mar 20.
3
Clinical Characteristics of Coronavirus Disease 2019 in China.《中国 2019 年冠状病毒病临床特征》
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
4
First Case of 2019 Novel Coronavirus in the United States.美国首例 2019 新型冠状病毒病例。
N Engl J Med. 2020 Mar 5;382(10):929-936. doi: 10.1056/NEJMoa2001191. Epub 2020 Jan 31.
5
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.多发性硬化症患者接受芬戈莫德、那他珠单抗、利妥昔单抗和注射治疗的感染风险。
JAMA Neurol. 2020 Feb 1;77(2):184-191. doi: 10.1001/jamaneurol.2019.3365.
6
Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers.克拉屈滨片对多发性硬化症患者淋巴细胞亚群的影响：表面标志物的扩展分析
Ther Adv Neurol Disord. 2019 Jun 18;12:1756286419854986. doi: 10.1177/1756286419854986. eCollection 2019.
7
Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.奥瑞珠单抗输注在复发型和原发进展型多发性硬化症患者中的应用经验：来自 III 期随机 OPERA I、OPERA II 和 ORATORIO 研究的结果。
Mult Scler Relat Disord. 2019 May;30:236-243. doi: 10.1016/j.msard.2019.01.044. Epub 2019 Jan 28.
8
Targeting the S1P receptor signaling pathways as a promising approach for treatment of autoimmune and inflammatory diseases.针对 S1P 受体信号通路作为治疗自身免疫和炎症性疾病的有前途的方法。
Pharmacol Res. 2020 Apr;154:104170. doi: 10.1016/j.phrs.2019.02.009. Epub 2019 Feb 15.
9
Lymphopenia and risk of infection and infection-related death in 98,344 individuals from a prospective Danish population-based study.前瞻性丹麦基于人群的研究中 98344 例个体的淋巴细胞减少症与感染和感染相关死亡的风险。
PLoS Med. 2018 Nov 1;15(11):e1002685. doi: 10.1371/journal.pmed.1002685. eCollection 2018 Nov.
10
Infectious Complications of Multiple Sclerosis Therapies: Implications for Screening, Prophylaxis, and Management.多发性硬化症治疗的感染性并发症：对筛查、预防和管理的启示
Open Forum Infect Dis. 2018 Jul 16;5(8):ofy174. doi: 10.1093/ofid/ofy174. eCollection 2018 Aug.
Zotero 插件